Tablet
    111.
    发明授权
    Tablet 有权
    片剂

    公开(公告)号:US09320714B2

    公开(公告)日:2016-04-26

    申请号:US13082890

    申请日:2011-04-08

    IPC分类号: A61K9/28 A61K9/20

    CPC分类号: A61K9/2072

    摘要: The present invention can retain the volume of a tablet large without increasing the thickness of the tablet or the like dimension and prevents a plurality of tablets from sticking to each other even if they are subjected to a film-coating or the like treatment, so as to improve the yield. The tablet is a tablet (1) longer in one direction when seen in plan. The tablet (1) has side edges (6) each of which extends in a longitudinal direction and is formed in the shape of a curve projecting outwardly in plan view. The curve has a radius of curvature (R1) set to at least 1.5 times a length (L) of the tablet. This makes a projected area of the tablet (1) in plan view at least 97% with respect to a projected area of a standard elliptical tablet having opposite end portions each of which is formed by a semi-circle having a diameter of a width (W) of the tablet.

    摘要翻译: 本发明可以在不增加片剂厚度等的情况下保持片剂的体积,并且即使进行薄膜包衣或类似的处理也能防止多个片剂彼此粘附,因此 提高产量。 平板电脑是平板电脑(1)在计划中看到的时间长一个方向。 片剂(1)具有侧边缘(6),每个边缘沿纵向方向延伸并且形成为在平面图中向外突出的曲线形状。 曲线的曲率半径(R1)设定为片剂长度(L)的至少1.5倍。 这使得平面图(1)中的平板(1)的投影面积相对于具有相对端部的标准椭圆形片的投影面积至少为97%,每个端部均由直径为宽度的半圆形成 W)。

    HETEROCYCLIC COMPOUND
    114.
    发明申请
    HETEROCYCLIC COMPOUND 有权
    杂环化合物

    公开(公告)号:US20160039811A1

    公开(公告)日:2016-02-11

    申请号:US14779347

    申请日:2014-03-27

    IPC分类号: C07D471/04 C07D519/00

    CPC分类号: C07D471/04 C07D519/00

    摘要: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.

    摘要翻译: 提供具有优异的JAK抑制作用的化合物或其盐,并且可用作自身免疫性疾病(类风湿性关节炎,牛皮癣,炎性肠病,干燥综合征,白塞氏综合征,多发性硬化症,系统性狼疮)的预防或治疗剂 红斑狼疮等),癌症(白血病,子宫平滑肌肉瘤,前列腺癌,多发性骨髓瘤,恶病质,骨髓纤维化等)等。 本发明涉及由式(I)表示的化合物,其中每个符号如本说明书中所定义,或其盐。

    Peptide compound
    117.
    发明授权
    Peptide compound 有权
    肽化合物

    公开(公告)号:US09200051B2

    公开(公告)日:2015-12-01

    申请号:US14287514

    申请日:2014-05-27

    IPC分类号: C07K14/605

    CPC分类号: C07K14/605 A61K38/00

    摘要: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 SEQ ID NO: 1 (I)wherein each symbol is as defined herein.

    摘要翻译: 本发明提供了对GLP-1受体和GIP受体具有活化作用的新型肽化合物以及肽化合物作为药物的用途。 具体地,提供含有由式(I)表示的部分序列的肽或其盐和包含其的药物。 P1-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys- Trp-Leu-Leu-Lys-A29 SEQ ID NO:1(I)其中每个符号如本文所定义。

    Solid pharmaceutical composition
    120.
    发明授权
    Solid pharmaceutical composition 有权
    固体药物组成

    公开(公告)号:US09169238B2

    公开(公告)日:2015-10-27

    申请号:US12737612

    申请日:2009-07-29

    CPC分类号: C07D413/14

    摘要: The present invention relates to a solid preparation containing a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof, a pH control agent and a diuretic, which is superior in the stability and dissolution property of the compound represented by the formula (I) and the diuretic.

    摘要翻译: 本发明涉及一种固体制剂,其含有式(I)表示的化合物,其中每个符号如说明书中所定义,或其盐,pH控制剂和利尿剂,其稳定性和溶解性优异 的式(I)表示的化合物和利尿剂。